Since imidazolones have been found to be associated with their various biological activities such as potassium channel opener, phosphodiesterase III/IV inhibition, and crop protection, 1,2 this class of compounds has become a synthetic target for organic and medicinal chemists. Due to increased interest, several synthetic approaches of these compounds have been investigated via solution or solid-phase synthesis.
3 Among imidazolones, 2-aminoimidazolone containing the guanidine moiety is particularly an attractive scaffold due to its hydrogen bonding donor and acceptor abilities in the active sites of various proteins. 2-Aminoimidazolones (i-v) synthesized up to date are shown in Figure 1 4 and they exhibit various biological activities.
5 Based on this finding, we decided to synthesize new imidazolone derivatives (vi) bearing carbon instead of nitrogen at 2-position expecting that compound vi would offer different chemical or biological properties compared to 2-aminoimidazolones shown in Figure 1 . In this report, we wish to demonstrate the synthesis of 2-arylimidazolone (vi) via chemoselective addition of carbon nucleophile on variously substituted carbodiimides prepared from natural L-amino acids by using our previous method for construction of 3,4-dihydroquinazoline scaffold. 6 The complete synthetic route is shown in Scheme 1: Ester of amino acid (1) was treated with isocyanate/Et 3 N to give urea 2a-c in 54-82% yields. Since benzylisocyanate was commercially unavailable, compound 2d was prepared in 84% yield by treating amino acid (1) with benzylamine/ triphosgene/ i Pr 2 NEt (Table 1) . 7 Compound 2a-d were dehydrated with PPh 3 ·Br 2 /TEA to provide the desired carbodiimide 3a-d in 42-59% yields. 8 Finally, reaction of carbodiimide 3a-d with Grignard reagent or piperidine resulted in the formation of the corresponding 2-phenylimidazolone 5a and 2-piperidinylimidazolones 5 (e, g, i, and k) via tandem chemoselective addition on carbodiimidecyclization. The results are summarized in Table 1 and 2. In the case of L-phenylalanine (R 1 = benzyl), the reaction of 
carbodiimide 3a (R 1 = benzyl, R 2 = phenyl) with phenylmagnesium bromide successfully provided the desired compound 5a (R 1 = benzyl, R 2 = phenyl, R 3 = phenyl) in 56% yield. However, the reaction with methylmagnesium bromide, vinylmagnesium bromide, and isopropylmagnesium bromide did not afford the corresponding 2-alkyl-or 2-vinylimidazolone. In order to compare with the previous procedures, 4 2-piperidinylimidazolone 5e was prepared by reacting compound 3 with piperidine via guanidine intermediate 4e in 75% yield. This result was comparable to the previous procedure which is solid-phase synthesis of 2-aminoimidazolones.
4b
In the case of L-gylcine and L-leucine, the reaction of carbodiimides 3b and 3c (R 1 = H or isobutyl, R 2 = phenyl) with phenylmagnesium bromide did not afford the desired 2-arylimidazolones and only resulted in the decomposition of compound in contrast to the case of L-phenylalanine 5a. However, the reaction of 3b-d with piperidine provided 2-aminoimidazolones 5g, 5i, and 5k in quantitative yields, respectively. Compared with the previous papers, 4 our current results have some meaningful points: First, the previous paper (solid-phase synthesis) limits R 1 position to be only aromatic ring, but a hydrogen or alkyl group was also allowed at R 1 position in our result. Secondly, introduction of aromatic group at R 3 position of imidazolone ring may be a first example via tandem carbon nucleophilic addition on carbodiimide-cyclization to the best of our knowledge. Therefore, our method is no longer a limitation for introduction of amino-substitution at 2-position.
In conclusion, we have introduced an aromatic group in R 3 position of imidazolone ring and this may be the first example via tandem carbon nucleophilic addition on carbodiimide-cyclization to the best of our knowledge. Therefore, our method allows a variety of aromatic ring to be introduced at 2-position and no longer limited to amino-substituent, resulting in a diversity of imidazolone library. In addition, previous reports 4 (solid-phase synthesis) limits R 1 position to be only aromatic ring while our synthetic route allows a hydrogen or alkyl group in this position. o C. The reaction mixture was stirred for 5 hr at room temperature and treated with 100 mL of water. The mixture was extracted with CH2Cl2. The combined extracts were dried over anhydrous MgSO4, filtered, and concentrated to give solid, which was washed with petroleum ether and dried in vacuo to provide the desired urea compound 2a (10.6 g, 82%) as a white solid: 1 H NMR (CDCl3, 300 MHz) δ 7.30-7.06 (m, 10H, Ph), 6.84 (s, 1H, Ph-NH), 5.56 (1H, d, J = 7.9 Hz, CONH), 4.84 (1H, m, CHCO2Et), 4.18 (2H, q, J = 7.2 Hz, CHCO2CH2CH3), 3.14-3.05 (2H, m, PhCH2), 1.26 (3H, t, J = 7.2 Hz, CHCO2CH2CH3). General procedure for carbodiimide (3a): To a solution of urea 2a (9.5 g, 31.8 mmol) in 200 mL of dried CH2Cl2 was added Ph3P·Br2 (20.1 g, 47.6 mmol, 1.5 equiv.) followed by an addition of triethylamine (9.6 g, 95.2 mmol, 3.0 equiv.) at 0 o C and the reaction mixture was allowed to warm to room temperature overnight. The reaction mixture was treated with 100 mL of water and extracted with CH2Cl2. The combined extracts were washed with aqueous NaHCO3, dried over Na2SO4, and concentrated under reduced pressure to give an oily compound, which was purified with column chromatography (Hex.:EtOAc = 6:1) to provide the desired carbodiimide 3a (3.9 g, 59%) as yellow oil: 2, 139.8, 137.6, 136.6, 129.9, 129.6, 127.6, 125.4, 124.5, 62.5, 61.3, 40.7, 14.6 . General procedure for 2-phenylimidazolone (5a): To a stirred solution of carbodiimide 3a (550 mg, 1.87 mmol) in 20 mL of anhydrous THF was added PhMgBr (2.06 mL, 1 M solution in THF, 2.06 mmol, 1.1 equiv.) under nitrogen atmosphere at −78 o C and then reaction mixture was allowed to warm to 0 o C over 2 hr. After quenching with aqueous NH4Cl, the reaction mixture was extracted with EtOAc. The combined extracts were dried over Na2SO4 and concentrated under reduced pressure to give a crude compound, which was purified with column chromatography (Hex.:EtOAc = 5:1) to provide the desired 2-phenylimidazolone 5a (327 mg, 56%) as yellow solid: 1 H NMR (CDCl3, 300 MHz) δ m, Ph), m, Ph) 182.4, 162.2, 135.6, 134.4, 131.1, 130.6, 129.5, 128.8, 128.6, 128.5, 128.3, 127.3, 69.3, 37.8; IR (KBr) 3.58, 2942 , 2362 , 1738 , 1612 
